Asthma; Eosinophilic Clinical Trial
Official title:
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion in the Real Life Severe Asthma Patients
Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group
After patients signed informed consent, before (visit 1), after 4-5 months (visit 2), and after 12 months (visit 3) Dupilumab treatment began, the following techniques and measurements will be performed or collected: demographic data, blood analyses (eosinophil counts and total IgE), skin prick-test to common aeroallergens (only in the visit 1), asthma control test (ACT), sino-nasal outcome test (SNOT-22), test of adherence to inhalers (TAI), number of severe asthma exacerbations (in the previous year; in the visit 2, in the previous 4 months), oral and inhaled steroid daily doses received, spirometry, exhaled nitric oxide (FeNO), pulmonary volumes, carbon monoxide transference, oscillometry, and induced sputum (inflammatory cell counts and mucin profile [MUC1, MUC2, MUC5AC, MUC5B]). All patients will be performed at visits 1 and 3 in a 3D culture of primary nasal epithelial cells from asthmatic patients the pattern of gene and to identify new soluble biomarkers through quantitative proteomic analysis of culture supernatants. Also a chest CT scan with expiratory images will be done only in visits 1 and 3. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04742504 -
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
|
||
| Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
| Completed |
NCT04181190 -
Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
|
||
| Completed |
NCT04456270 -
Asthma Control in a Dutch Primary Care Population
|
||
| Not yet recruiting |
NCT05091385 -
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
|
||
| Recruiting |
NCT05078281 -
Patients With Severe Eosinophilic Asthma Treated With Benralizumab
|
||
| Recruiting |
NCT04512521 -
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
|
||
| Recruiting |
NCT05813288 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
|
Phase 3 | |
| Recruiting |
NCT04319705 -
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
|
Phase 4 | |
| Recruiting |
NCT06288516 -
BenRalizumab Effect on Airway Remodeling in Severe asTHma
|
Phase 4 | |
| Active, not recruiting |
NCT03733535 -
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
|
N/A | |
| Not yet recruiting |
NCT05241769 -
The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
|
||
| Not yet recruiting |
NCT05404763 -
Mepolizumab and Physical Activity in Severe Asthma
|
||
| Not yet recruiting |
NCT04924478 -
Evaluation of Volatile Organic Compounds in Mepolizumab Therapy
|
||
| Recruiting |
NCT05763121 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
|
Phase 3 | |
| Recruiting |
NCT05748600 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
|
Phase 3 | |
| Completed |
NCT03453021 -
Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
|
||
| Active, not recruiting |
NCT04612556 -
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
|
||
| Completed |
NCT04710134 -
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
|
Phase 4 | |
| Not yet recruiting |
NCT05144087 -
The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma
|